PDS Biotechnology Shares Face Market Pressure Despite Clinical Promise

PDS Biotechnology Corporation’s stock is experiencing significant downward momentum amid intense volatility, even as the company reports encouraging clinical trial developments. The biotech firm’s shares have declined for four consecutive trading sessions, reflecting persistent selling activity that overshadows recent positive medical news.

Just two days before releasing promising study data, PDS Biotech announced a capital raising initiative on November 11. The company proposed issuing 5.8 million shares at $0.91 each to strengthen its financial position.

The financing move revealed concerning financial metrics:
* Estimated gross proceeds of $5.3 million
* Potential for an additional $5.8 million if all warrants are exercised
* Third-quarter losses totaling $9.0 million
* Cash reserves diminished to Read more...